effects on haemostasis. 5 HES with a high molecular weight (MW) and a high degree of substitution (DS) (hetastarch; MW 450 kDa, DS 0.7) reduced concentrations of VIIIR:Ag and VIIIR:RCo more than HES with lower MW and a lower DS [low-molecular weight (LMW) HES; MW 200±260 kDa, DS 0.5]. 6 Abnormal platelet function occurs more often after high-molecular weight (HMW) HES. 7 Reports of HES reducing blood coagulation and increasing bleeding generally relate to giving HMW HES and HES with a high degree of substitution (DS 0.7). 8 Consequently, an HES preparation with a lower MW (130 kDa) and a lower DS (0.4) has been developed to reduce the impairment of coagulation. 9 10 Another way to reduce this effect is by modifying the HMW HES preparation. Hextend â is a modi®ed, physiologically balanced 6% hetastarch solution (molar substitution 0. . 11 This HES preparation impairs coagulation less than the standard HMW HES. 11 12 We used activated thrombelastography (TEG) to assess the effects of volume replacement with Hextend â on measures of coagulation in patients undergoing major abdominal surgery, compared with another HES preparation (MW 130 kDa, DS 0.4) and RL.
Methods

Patients
After ethics approval and with informed consent, we included 63 consecutive patients undergoing elective major abdominal surgery for malignancy. We excluded patients with renal insuf®ciency (serum creatinine >150 mmol litre ±1 ; blood urea nitrogen >6 mmol litre ±1 ), liver dysfunction (aspartate aminotransferase >40 U litre ±1 , alanine aminotransferase >40 U litre ±1 ), anaemia (haemoglobin <10 g dl ±1 ), preoperative coagulation abnormalities [platelet count <100 nl ±1 ; activated partial thromboplastin time (aPTT) >70 s; ®brinogen <2 g dl ±1 ; antithrombin III <40%], patients taking heparin, vitamin K antagonists, corticosteroids or cyclooxygenase inhibitors, and patients with severe cardiac insuf®ciency (NYHA class III±IV).
The patients were allocated prospectively to one of the following groups using a sealed envelope system: group I (n=21), volume therapy with Hextend ); group III (n=21), treatment with 6% HES 130/0.4 (Fresenius, Bad Homburg, Germany).
Volume replacement was started after induction of anaesthesia (after baseline data had been obtained) and continued for 48 h until the morning of the second postoperative day. Volume was infused to keep central venous pressure (CVP) between 8 and 12 mm Hg. Red blood cells were transfused when haemoglobin was <8 g dl ±1 , and fresh frozen plasma was given if coagulation measures were abnormal (aPPT >60 s, prothrombin time <50%, ®brinogen <2 g litre ±1 ) and bleeding occurred. We gave RL 500 ml h ±1 to all patients during surgery. Additional RL was given to replace¯uid losses from sweating and gastric tubes and RL was used as a solvent for drugs. When mean arterial pressure (MAP) was <50 mm Hg despite adequate ®lling pressure volume (CVP >10 mm Hg), epinephrine was given. Norepinephrine was added if volume therapy and dopamine did not keep MAP >50 mm Hg.
Premedication consisted of oral midazolam 1 h before surgery. Epidural anaesthesia was used in all patients. General anaesthesia was induced with thiopental 5 mg kg ±1 and fentanyl 3 mg kg ±1 and neuromuscular block was achieved with vecuronium 0.1 mg kg ±1 . Anaesthesia was maintained with fentanyl, des¯urane and vecuronium, titrated according to the patients' needs. In all patients, mechanical ventilation was with 50% air in oxygen to keep arterial oxygen saturation >95% and end-expiratory carbon dioxide between 35 and 40 mm Hg. ECG, arterial blood pressure and CVP were monitored continuously. Fluid warmers and blankets were used during surgery to maintain body temperature. After surgery, mechanical ventilation was continued as necessary until the patient was ready for tracheal extubation (stable circulation, spontaneous breathing with adequate blood gases and oesophageal temperature >36°C). The patients were managed by anaesthetists who were not involved in the study and were masked to the volume therapy.
Coagulation measurements
Standard coagulation variables [antithrombin III (AT III), ®brinogen, platelet count, aPTT] were measured from arterial blood samples using routine laboratory methods. Another 5 ml of citrated blood was taken for activated TEG using a four-channel TEG analyser (roTEGÔ; Nobis Diagnostics, Endingen, Germany). This modi®cation of the conventional TEG system uses a different transducer that makes it less susceptible to mechanical stress, movement and vibration. 13 14 The method is based on optical detection of the movement of a disposable plastic sensor attached to a short axle mounted on a ball-bearing. The sensor is inserted into the clotting blood. TEG measurements were made within 10 min after blood sampling using a semiautomatic pipetting system after adding different activators to the blood sample (activated TEG). To assess intrinsic TEG (InTEG), clot formation was measured after recalci®cation of 300 ml of whole blood with 20 ml of 0.2 M calcium chloride and adding a surface activator (partial thromboplastin from rabbit brain; 20 ml). To assess extrinsic TEG (ExTEG), clot formation was measured after adding tissue thromboplastin (rabbit brain extract). To assess aprotinin TEG (ApTEG), ExTEG was measured in the presence of inhibition of ®brinolytic activity by aprotinin (aprotinin solution equivalent to 10 000 kallikrein inhibitor units ml ±1 ). Comparison of this result with the ExTEG value gives a measure of ®brinolytic activity.
All measurements were made by the same person. Measurements were made after induction of anaesthesia and before surgery, immediately after surgery, 5 h after surgery and on the mornings of the ®rst and second days after surgery. The patient outcomes were followed-up for 30 days after surgery.
Statistics
A power analysis was done before the study started to determine the necessary number of patients in each group. The data used were from a previous TEG study on the effects of HES 130/0.4. 15 A 50% increase in reaction time (r) after treatment was taken to be the minimum clinically important difference we wished to detect. For an alpha error of 0.05 (two-sided) and type II error of 0.2, a total of 21 
Results
Patient details and the type of surgery are given in Table 1 . There were no obvious differences between the groups. Signi®cantly more blood and blood products were given to the Hextend â -treated patients than to the two other groups (Table 1) . Signi®cantly more HES 130/0.4 [2590 (260) ml] than Hextend â [1970 (310) ml] was given in the study period (Table 2 ). Blood loss was greatest in the Hextend â group, but did not differ between RL-and HES 130/0.4-treated patients (Table 2 ). There was no signi®cant correlation between blood loss and TEG measurements. Cardiovascular measurements and haemoglobin changes were similar in all groups (Tables 3 and 4) . Standard coagulation tests showed no signi®cant differences between the groups, except for small differences in ®brinogen (RL, signi®cant difference) and AT III concentrations on the ®rst and second days (Table 4) .
TEG data were similar and within the normal range in all three groups at baseline (Figs 1±3). Using ExTEG and InTEG, CT and CFT were prolonged most in the Hextend â -treated patients and were greater than in the two other groups immediately after surgery, 5 h after surgery and on the ®rst day (Figs 1 and 2 ). On the second day, CT and CFT in the Hextend â group were still greater than baseline but were not different from values for the other two groups. Changes in ExTEG-MCF/ApTEG-MCF were signi®cantly more pronounced in the Hextend â patients than in the other two groups, indicating more ®brinolysis (Figs 1 and 3 ).
Volume therapy with RL caused shortening of the CT (ExTEG, InTEG) at the end of surgery and 5 h after surgery (Figs 1 and 2) , indicating moderate hypercoagulability. This returned to normal later in the study period (®rst and second days) (Figs 1 and 2 ).
Discussion
The use of HES as a plasma substitute is sometimes restricted primarily because of reports of altered coagulation.
2 3 8 HMW HES and highly substituted hydroxyethyl starch preparations can impair blood clotting and increase postoperative bleeding. 8 16 A modi®ed HMW HES (Hextend â ) and a new LMW/low-substituted HES (6% HES 130/0.4) have been developed to prevent these adverse effects.
We used TEG to assess the effects of the different plasma substitutes, as measuring plasma concentrations of coagulation proteins and other markers of coagulation appears to be a very simplistic approach for complete assessment of the complex changes that can occur in haemostasis. 17 TEG (10) 68 (10) 71 (11) 79 (11) 76 (10) HES 130/0.4
81 (11) 60 (12) 69 (13) 73 (9) 74 (11) appears to be a more complete means of following the dynamic process of coagulation compared with conventional tests of haemostasis. 18 19 TEG monitors the kinetics of the complete haemostatic process, whereas with plasma coagulation tests only the speed of ®brin formation is assessed. TEG examines the interplay of the protein coagulation cascade, ®brinogen, and platelet function. TEG measurements can assist management of coagulation during and after surgery, and reduce blood loss and use of blood and blood products. 18 20 21 We used modi®ed, activated TEG instead of conventional (`non-activated') TEG because different features of the coagulation process can be detected sooner and better by activated TEG. 22 23 We found that Hextend â had the most adverse effects on activated TEG monitoring, whereas HES with a low MW and low DS affected coagulation less and RL caused a small increase in coagulation. Our results contradict other in vitro and in vivo studies, which did not show that Hextend â had adverse effects on coagulation, except those expected as a result of haemodilution. 11 12 An in vitro study with different dilutions of plasma with Hextend â (up to 25% plasma/75% Hextend â ) found no adverse effect on coagulation, 12 with possibly a protective effect on factors sensitive to prothrombin time (I, II, VII, X), on functional ®brinogen, and on factors of factor VIII macromolecular complex components (FVIII:C, VIII:vWF, VIII:vWF multimers), and no evidence of disseminated intravascular coagulation or procoagulant activation. The value of in vitro coagulation studies is not clear, because in such studies the effects of surgery on the coagulation process are absent. Even after minor surgery (mammoplasty), a hypercoagulable state was seen, whereas after complex, lengthy surgery hypocoagulability may also be present. 24 HMW HES (hetastarch) can affect coagulation by adverse effects on both von Willebrand factor and platelet aggregation. 8 Most reports of impaired haemostasis with HES are associated with this ®rst-generation HMW HES. 2 8 A study of patients undergoing major surgery compared Hextend â with standard HMW HES (hetastarch), and found no differences in perioperative blood transfusion and estimated blood loss. 11 Onset of clot formation (r ± CT) was slower in the patients treated with hetastarch compared with those given Hextend â , and other TEG variables showed no differences between the two groups. Why the modi®ed,`balanced' Hextend â solution is almost free of this side-effect on coagulation is not clear. The authors speculated that the addition of Ca 2+ , lactated buffer and physiological concentrations of glucose and lower Cl ± concentrations gave Hextend â a favourable side-effect pro®le. 11 Our study using TEG monitoring in patients found no bene®t of Hextend â administration either in onset of coagulation (r ± CT)] or in the kinetics of clot formation (k ± CFT). The difference of ExTEG MCF and ApTEG MCF (TEG measured in the presence of an inhibitor of ®brinolysis) showed reduced MCF [standard TEG: maximal amplitude (MA)] with Hextend â compared with the new HES 130/0.4.
The shorter coagulation time in our RL-treated patients supports previous studies. In in vitro and in vivo TEG studies, Ruttman and colleagues 25 26 showed that haemodilution per se increased the coagulability of whole blood (decrease in r and k; increase in MA) most likely due to induction of thrombin formation. This hypercoagulability was greater in saline-than in gelatin-diluted samples. In an in vitro TEG study, 27 only extreme haemodilution with RL (10:10) increased the k and MA values, whereas the r value remained unchanged. Ng and Lo 28 also reported increased coagulability when surgical blood loss was replaced with crystalloids. Monkhouse 29 showed that diluting plasma with saline increases the thrombin activity two-to three-fold. This increase in thrombin activity in diluted samples was assumed to result from decreased antithrombin action rather than any real increase in thrombin generation. Similar changes in thrombin generation occur in vivo after giving large amounts of saline solution for acute haemorrhage. 29 This crystalloid-induced increase in coagulability could predispose patients to deep vein thrombosis. 30 The new LMW low-substituted HES (HES 130/0.4) has better physicochemical properties compared with other HES solutions 31 and its effect on coagulation also appears to be favourable. Konrad and colleagues 32 used an in vitro haemodilution model and SONOCLOT analysis to measure the effects of this HES preparation on haemostasis: HES 130/0.4 affected clot maturation signi®cantly less than other HES preparations and it had less effect on other aspects of clot formation and retraction. Clinical studies with HES 130/0.4 in orthopaedic 10 and cardiac patients 9 reported bene®cial effects on bleeding tendency and the use of blood and blood products. In summary, modi®cation of an HMW starch did not eliminate adverse effects on coagulation when assessed by activated TEG. Reducing the molecular weight and the degree of substitution (HES 130/0.4) caused less impairment of haemostasis. Volume replacement only with crystalloids (RL) in patients undergoing major abdominal surgery was associated with moderate, short-lasting hypercoagulability.
